Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Parton

Showing results (81-90 of 83) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 83 results.
Elife|January 20, 2022
Absolute quantitation of individual SARS-CoV-2 RNA molecules provides a new paradigm for infection dynamics and variant differencesJeffrey Y Lee, Peter A C Wing, Dalia S Gala, et al.
The Journal of Cell Biology|May 5, 2023
Systematic analysis of YFP traps reveals common mRNA/protein discordance in neural tissuesJoshua S Titlow, Maria Kiourlappou, Ana Palanca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2022
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerC E Geyer, J E Garber, R D Gelber, et al.
Pageof 9

Showing results (81-90 of 83) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 83 results.
Elife|January 20, 2022
Absolute quantitation of individual SARS-CoV-2 RNA molecules provides a new paradigm for infection dynamics and variant differencesJeffrey Y Lee, Peter A C Wing, Dalia S Gala, et al.
The Journal of Cell Biology|May 5, 2023
Systematic analysis of YFP traps reveals common mRNA/protein discordance in neural tissuesJoshua S Titlow, Maria Kiourlappou, Ana Palanca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2022
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerC E Geyer, J E Garber, R D Gelber, et al.
Pageof 9